Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical Trial

Stock Information for Anixa Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Anixa Biosciences Inc.

Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board
Anixa Biosciences 2024 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties
Anixa Biosciences Announces Presentation at 24th Annual World Vaccine Congress
Anixa Biosciences Announces Participation in 2024 NeauxCancer Oncology Conference
Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology
Anixa Biosciences to Present at Sidoti Micro-Cap Virtual Conference on January 17, 2024
Anixa Biosciences to Present at Biotech Showcase 2024
Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.